Collegium Pharmaceutical (NASDAQ:COLL) Upgraded to “Strong-Buy” by Zacks Investment Research

Zacks Investment Research upgraded shares of Collegium Pharmaceutical (NASDAQ:COLL) from a strong sell rating to a strong-buy rating in a research note issued to investors on Monday, Zacks.com reports. Zacks Investment Research currently has $23.00 price target on the specialty pharmaceutical company’s stock.

According to Zacks, “Collegium Pharmaceutical Inc. is a specialty pharmaceutical company. It develops and commercializes prescription and over-the-counter pharmaceuticals for the treatment of central nervous system, respiratory and skin related disorders. The Company’s product candidate consists of COL-195, COL-196, COL-171, COL-003 and COL-172 which are in different clinical trial. It developed a formulation platform technology, DETERx, for the treatment of chronic pain. Collegium Pharmaceutical Inc. is based in CUMBERLAND, United States. “

Several other research firms have also commented on COLL. HC Wainwright lowered their price objective on shares of Collegium Pharmaceutical from $33.00 to $28.00 and set a buy rating for the company in a research report on Friday, August 6th. Needham & Company LLC initiated coverage on shares of Collegium Pharmaceutical in a research report on Friday, September 17th. They set a buy rating and a $32.00 price objective for the company. Finally, Cantor Fitzgerald lowered shares of Collegium Pharmaceutical from an overweight rating to a neutral rating and lowered their target price for the stock from $30.00 to $22.00 in a report on Friday, August 6th.

COLL opened at $20.39 on Monday. The stock has a market capitalization of $725.15 million, a price-to-earnings ratio of 7.50, a PEG ratio of 0.71 and a beta of 0.89. The company has a fifty day moving average of $21.43 and a 200 day moving average of $22.71. Collegium Pharmaceutical has a fifty-two week low of $17.24 and a fifty-two week high of $26.91. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.32 and a current ratio of 1.40.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Thursday, August 5th. The specialty pharmaceutical company reported $0.27 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.34 by ($0.07). The company had revenue of $82.94 million for the quarter, compared to analysts’ expectations of $84.29 million. Collegium Pharmaceutical had a net margin of 32.73% and a return on equity of 22.59%. On average, equities research analysts forecast that Collegium Pharmaceutical will post 1.38 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently bought and sold shares of COLL. Captrust Financial Advisors acquired a new stake in Collegium Pharmaceutical in the 1st quarter worth approximately $27,000. PNC Financial Services Group Inc. lifted its stake in Collegium Pharmaceutical by 245.9% during the 2nd quarter. PNC Financial Services Group Inc. now owns 1,266 shares of the specialty pharmaceutical company’s stock valued at $30,000 after acquiring an additional 900 shares during the period. Royal Bank of Canada lifted its stake in Collegium Pharmaceutical by 344.3% during the 2nd quarter. Royal Bank of Canada now owns 3,110 shares of the specialty pharmaceutical company’s stock valued at $74,000 after acquiring an additional 2,410 shares during the period. Shell Asset Management Co. acquired a new stake in Collegium Pharmaceutical during the 1st quarter valued at approximately $99,000. Finally, Ensign Peak Advisors Inc acquired a new stake in Collegium Pharmaceutical during the 1st quarter valued at approximately $102,000.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc operates as a pharmaceutical company. The firm engages in the development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR.

See Also: What is a resistance level?

Get a free copy of the Zacks research report on Collegium Pharmaceutical (COLL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.